Le Lézard
Classified in: Science and technology
Subject: PDT

BlipCut V3.0 Launches with AI Clipping Feature to Boost Efficiency for Creators and Businesses


NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BlipCut, the leading AI-powered video translation platform, is excited to announce the release of its V3.0.0 update, bringing a new feature - BlipCut AI Clipping - designed to help creators as well as teams to improve the efficiency of video creation.

BlipCut AI Clip Maker converts long video to viral short videos, making them suitable for a wide range of social media platforms such as YouTube, Instagram and TikTok. Now, creators can spend more time on storytelling and innovation while BlipCut makes the technical adjustments.

Key Features of BlipCut AI Clip Maker:

About BlipCut:

BlipCut is an industry-leading AI video translation platform that allows users to break language barriers with ease. With features like batch translator, subtitle translation, AI voiceover, ai clip generator, and support for 130+ languages, BlipCut is the go-to solution for content creators, educators, and businesses worldwide.

To know more, you may visit: https://videotranslator.blipcut.com/

Our Social Media:

YouTube: https://www.youtube.com/@BlipCut_Online
X/Twitter: https://twitter.com/BlipCutofficial
Facebook: https://www.facebook.com/blipcut
Discord: https://discord.gg/vk4Z2YWGsG

This release was issued through Send2Press® on behalf of the news source. For more information, visit Send2Press Newswire at https://www.send2press.com/

SOURCE BlipCut


These press releases may also interest you

at 12:55
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...

at 12:35
bluebird bio, Inc. today announced new and updated data from LYFGENIAtm (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at...

at 12:05
ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced positive...

at 12:05
This weekend, a class action lawsuit was filed against Apple on behalf of thousands of survivors of child sexual abuse for knowingly allowing the storage of images and videos documenting their abuse on iCloud and the company's defectively designed...



News published on and distributed by: